MGI Tech Co., Ltd. Spain

or connect with us on Twitter, LinkedIn or YouTube.

ABOUT ABL DIAGNOSTICS

ABL Diagnostics S.A. (ABLD) is a worldwide leading international company offering innovative and proprietary molecular biology assays and end-to-end solutions intended to be used for molecular detection by Polymerase Chain Reaction (PCR) – UltraGene® and for genotyping through DNA sequencing – DeepChek®.

ABL Diagnostics, based in Woippy, is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products are generating recurring revenues and cover one of the largest portfolio of microbiology applications.

ABL Diagnostics commercializes its entire line of products on a worldwide basis through its own sales team and through a network of exclusive distributors active on all continents. ABL Diagnostics clients are academic clinical pathology labs, private reference labs and researchers willing to implement an innovative and robust microbiology content in constant expansion.

For further information, please visit www.abldiagnostics.com.

Photo - https://mma.prnewswire.com/media/2400133/MGI_Europe_Africa_ABL_Diagnostics.jpg
Logo - https://mma.prnewswire.com/media/2329841/MGI__Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/mgi-showcases-life-science-excellence-at-escmid-global-2024-with-latest-dnbseq-e25-sequencer-and-new-partnership-with-abl-diagnostics-302130291.html